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Although irinotecan 350mgm
 2 is a standard option for relapsed/refractory advanced colorectal cancer, there is some evidence that
suggests that a higher dose may be more effective, with acceptable tolerability, following 5-fluorouracil (5-FU). This study assessed the
optimal dosing strategy for irinotecan, along with treatment efficacy and safety. A total of 164 patients with metastatic colorectal
cancer progressing after failure on 5-FU or raltitrexed received either 350mgm
 2 irinotecan (Group A; n¼36) or 250, 350 or
500mgm
 2, according to individual patient tolerance (Group B; n¼62) or based on risk factor optimisation (Group C; n¼66).
There were no complete responses. There was a trend towards a higher overall response rate in Group B (13%) than in Groups A
(8%) and C (9%). Tumour control growth rate was high in all three groups: 58% in group A, 60% in Group B and 50% in Group C. A
total of 34% of patients in Group B and 9% in Group C were able to receive a dose of 500mgm
 2. Median duration of response and
time to progression were significantly longer in Groups A and B compared with Group C. No significant between-group differences
for any adverse events were seen, although there was a small trend towards better tolerability in Group B. Individual dose escalation
based on patient tolerance may allow more patients to receive a higher irinotecan dose without causing additional toxicity and can be
an appropriate patient management strategy.
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Irinotecan (CPT-11, Campto
s) – a semisynthetic, water-soluble
derivative of the plant alkaloid camptothecin – is the standard of
care in the treatment of advanced colorectal cancer when 5-
fluorouracil (5-FU)-based therapy has failed (Cunningham et al,
2001). Phase II trials have demonstrated objective response rates of
16–27% in pretreated patients, with stabilisation of disease in a
further 40–60% of patients (Rougier et al, 1997; Van Cutsem et al,
1999). Median overall survival rates of up to 10 months are
achievable when irinotecan is used in relapsed/refractory color-
ectal cancer (Shimada et al, 1993; Rothenberg et al, 1996, 1999;
Pitot et al, 1997; Rougier et al, 1997; Van Cutsem et al, 1999). Two
European phase III trials investigating the efficacy and safety of
irinotecan, following 5-FU failure in advanced colorectal cancer,
have demonstrated significant improvements in survival compared
with best supportive care and 5-FU (Cunningham et al, 1998;
Rougier et al, 1998). The main adverse events accompanying
treatment with irinotecan in these trials were diarrhoea, neutro-
penia, fatigue, nausea and vomiting.
Although 350mgm
 2 as an intravenous infusion every 3 weeks
is the standard recommended dosage of irinotecan, pharmacoki-
netic parameters of irinotecan-lactone and the active metabolite
SN-38-lactone vary between individuals (Xie et al, 2002). This may
be attributed to differences in the levels of the enzymes that
metabolise irinotecan, notably carboxylesterase for SN-38.
Furthermore, the variable interindividual patient exposure to SN-
38 has been identified as an important determinant of toxicity
(Mathijssen et al, 2002).
At the same time, there is convincing evidence of a dose–
response relationship, and therefore a rationale for increasing
doses when possible. In a phase I trial by Abigerges et al (1995),
there were two recommended doses: 350mgm
 2 without high-
dose loperamide and 600mgm
 2 with high-dose loperamide. With
the exception of one responder treated at 260mgm
 2, all objective
responses were observed at dose levels above 350mgm
 2.
Merrouche et al (1997) provided further support for this from a
phase I trial in which an increased tumour response was seen at an
irinotecan dose level of 500mgm
 2.
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sThus, these data suggest that a fixed-dose strategy for
administration of irinotecan may not be optimal for all patients,
thereby comprising treatment. The interindividual variability in
pharmacokinetic parameters and dose–response relationship
provided the rationale for investigating a dose optimisation
strategy for irinotecan (Chabot et al, 1995). The present study
investigated different strategies, using doses of irinotecan up to
500mgm
 2, as single-agent therapy in the treatment of patients
with metastatic colorectal cancer resistant to 5-FU.
METHODS
Patients
Eligibility criteria included metastatic, histologically proven
adenocarcinoma of the colon or rectum progressing on 5-FU-
based chemotherapy (adjuvant and/or palliative); administration
of p2 5-FU-based regimens in the adjuvant setting or p1 in the
palliative setting; World Health Organization (WHO) performance
status (PS) of p2; adequate haematological, renal and hepatic
function. Exclusion criteria included prior treatment with topoi-
somerase-I inhibitors; evidence of central nervous system metas-
tases; prior history of chronic diarrhoea; current infection; or any
other serious illness or medical condition.
Study design and conduct
This was a prospective, randomised, multicentre, open-label, phase
II study. The study was conducted in accordance with the
Declaration of Helsinki (Hong Kong revision, 1989) and with the
approval of the Ethics Committee (Institutional Review Board) at
each participating centre. Written informed consent was obtained
from each patient prior to his or her enrolment into the trial. An
independent Monitoring Committee regularly assessed the safety
and efficacy issues and reviewed the conduct of the study if
needed. An External Response Review Committee (ERRC) assessed
tumour responses without knowledge of the randomisation arm.
The aim of the study was to determine the optimal dosing strategy
in terms of efficacy and safety of single-agent irinotecan (by
individual dose optimisation based on patient tolerance to
treatment, or optimisation based on specific baseline risk factors)
in the treatment of 5-FU-resistant patients with metastatic
colorectal cancer. The primary efficacy endpoint was the overall
response rate.
Dosing scenarios Patients were randomised to one of three
groups (A, B and C (outlined below)), each group receiving
irinotecan as a 30min intravenous infusion scheduled every 21
days. This dosing interval could be extended to a maximum of 35
days in the event of persistent toxicity to allow satisfactory
recovery from the previous cycle. Doses o250mgm
 2 or
4500mgm
 2 were not used in this study; patients who exhibited
significant toxicity at 250mgm
 2 were withdrawn from the study.
Group A was the reference group in which a fixed dose of
350mgm
 2 of irinotecan was administered on Day 1. In
subsequent cycles, the dose of irinotecan could be decreased
(but not increased) according to the presence of significant toxicity
at this dose.
Groups B and C investigated dosing scenarios to select patients
for whom the higher dose of irinotecan (500mgm
 2) could be
optimally used. Patients randomised to Group B received
irinotecan at a starting dose of 250mgm
 2 followed by increasing
doses (350 and 500mgm
 2) depending on the tolerance observed
in the preceding cycle. In the event of significant toxicity, dose
reductions were implemented.
In Group C, the irinotecan dose was based on protocol-defined
toxicity risk factors identified at baseline: grade 3–4 neutropenia
(bilirubin 470% upper limit of normal (UNL), haemoglobin
o12gdl
 1, 43 organs involved) and/or grade 3–4 diarrhoea
(PSX1, creatinine 470% UNL (Freyer et al, 2000)). Patients could
be started at an irinotecan dose of 500mgm
 2 in the absence of
toxicity risk factors. The starting dose of irinotecan was
350mgm
 2 in patients with one risk factor or one factor from
each group, and 250mgm
 2 for patients with 42 risk factors or
two factors from the same group. The dose was not escalated, but
could be reduced to 250mgm
 2 in the event of significant
treatment-emergent toxicity.
Concomitant treatments and follow-up
Antiemetic drugs were administered as premedication to irinote-
can infusions. Atropine was permitted for acute anticholinergic
symptoms and loperamide (or similar) for delayed diarrhoea. In
addition, preventative oral antibiotic therapy (e.g. an oral
fluoroquinolone) was administered to patients with persistent
(448h) grade 4 diarrhoea or for diarrhoea associated with grade
3–4 neutropenia or fever. No granulocyte-colony-stimulating
factor (G-CSF) support was allowed. All patients were followed
until disease progression, unacceptable toxicity or death occurred,
or the patient chose to withdraw from the trial. In all cases, in each
group where toxicity necessitated a dose reduction, delay or study
treatment termination, the patient was followed up until the event
had resolved.
Efficacy, safety and pharmacokinetic evaluations
Tumour response rate, the primary efficacy end point, was
measured according to WHO criteria and evaluated by the ERRC.
Response was defined as complete (CR) plus partial (PR) response
and as tumour growth control in terms of stabilisation of disease
(PR plus no change/stable disease). Secondary efficacy variables
were the duration of response and disease stabilisation, time to
progression (TTP), time to treatment failure (TTF) and overall
survival. The duration of response was measured from the first day
of infusion of irinotecan to the first date that disease progression
was noted or to the date of death for any reason. Time to
progression was calculated from the date of randomisation to the
first documented date of progression or the date of death for any
reason. Time to treatment failure was the period between the date
of randomisation and the date of tumour progression or treatment
discontinuation for any reason. Survival was defined as the time
between randomisation and death. Efficacy evaluations were
performed using intent-to-treat (ITT) and per-protocol (eligible
and evaluable) patient populations.
The safety population comprised all patients who had started at
least one infusion of study treatment. Safety was assessed
according to the National Cancer Institute Common Toxicity
Criteria or, if this was not applicable, graded as mild, moderate,
severe or life threatening. The safety analysis was based on the
worst grade by patient and by cycle. Deaths during the trial and up
to 30 days from the last infusion were recorded.
Pharmacokinetic evaluations were performed using a population
approach (Chabot et al, 1995; Canal et al, 1996). At 30min prior to
infusion, and at 5min and 3–4h postinfusion (an additional
sample was collected at 24h postinfusion in some cases), three 5ml
blood samples (plus one predrug sample) were taken for analysis
at the first cycle of chemotherapy for Groups A and C, and at the
first, second and third cycles for Group B. Plasma levels of
irinotecan and SN-38 were measured using reverse-phase high-
performance liquid chromatography with camptothecin as an
internal standard. Peak plasma concentration (Cmax) and the area
under the plasma concentration–time curve (AUC) were calcu-
lated for both irinotecan and SN-38. In addition, total body
clearance was calculated for irinotecan, and the time to reach Cmax
(tmax) as well as the AUC normalised to l mg of irinotecan (AUCN)
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swere calculated for SN-38. A three- and two-compartment model
was used for irinotecan and SN-38, respectively.
Statistical considerations
Using the hypothesis that the response rate in Groups B and C
would be 20%, a total of 64 patients in each of these groups were
required to yield a confidence interval (CI) band of p20%. For the
reference group (Group A), the number of subjects randomised
was half that of Groups B and C. The 95% CIs were estimated for
response, using the exact method. Confidence intervals on median
values were estimated using the method described by Brookmeyer
and Crowley (Simon et al, 1985). Descriptive statistics only were
used for the pharmacokinetic parameters in each group.
RESULTS
Patients
A total of 164 patients entered the study: 36 in Group A, 62 in
Group B and 66 in Group C (Table 1). The majority of patients
(X97%) had received surgery and 20–30% had received radio-
therapy and/or prior adjuvant chemotherapy. Based on the
assessment of baseline risk factors previously described, 23
(35%) patients in Group C were assigned to receive a starting
dose of 250mgm
 2 irinotecan, 37 (56%) patients to 350mgm
 2
and six (9%) patients to 500mgm
 2.
A total of 144 (88%) patients (31, 51 and 62 in Groups A, B and
C, respectively) were eligible and evaluable for the efficacy
analyses. Nine patients were ineligible due to major protocol
violations (41 line of palliative chemotherapy, and past or
concurrent history of neoplasm other than colorectal adenocarci-
noma in one patient) and 12 patients (not mutually exclusive) were
nonevaluable for response. Early discontinuation because of
adverse events rendered eight patients nonevaluable.
Extent of exposure to irinotecan
The median dose intensity of irinotecan was similar in the three
arms: 114.21mgm
 2week
 1 (95% CI 76.14–119.21) in Group A,
101.36mgm
 2week
 1 (95% CI 68.22–158.17) in Group B and
106.69mgm
 2week
 1 (95% CI 67.11–170.93) in Group C.
However, the median cumulative dose was higher in Group A
(1948.80mgm
 2) than in Groups B (1564.26mgm
 2) and C
(1326.77mgm
 2), possibly due to the longer median treatment
time in this group (18 weeks, compared with 16 and 13 weeks in
Groups B and C, respectively).
The percentage of cycles delivered at doses of 250, 350 and
500mgm
 2 were as follows: 3, 92 and 0% (as this was not an
option) in Group A; 41, 30 and 27% in Group B; and 33, 51 and 8%
in Group C. A few cycles in each group were given at intermediate
doses or at doses above 525mgm
 2.
In Group B, the only dose escalation option, 63% of patients had
at least one dose escalation from the 250mgm
 2 start dose.
More than 80% of patients in each group did not require dose
reduction. A total of 36–40% of patients experienced a cycle delay
(Table 2). Although the majority of dose reductions in each group
were made for treatment-related reasons (mostly nonhaematolo-
gical adverse events across all arms), the majority of cycle delays
occurred for reasons unrelated to treatment.
Efficacy
Response rate In the total (ITT) patient population (n¼164), the
overall response rates were 8, 13 and 9% in Groups A, B and C,
respectively (Table 3). There were no CRs. Tumour growth control
rates were higher in Groups A and B and the rates of progressive
disease were lower, compared with Group C (Table 3). The pattern
of response across the groups was maintained in the per-protocol
(eligible and evaluable) patient population (n¼144), with overall
response rates (no CR) of 10, 16 and 10% in Groups A, B and C,
respectively. Corresponding tumour growth control rates were 61,
65 and 53%.
Responses occurred at all dose levels (Table 3). However, there
were only two responses at the 250mgm
 2 dose of irinotecan, both
in Group C. Although it is difficult to interpret the data based on
the small patient numbers in this study, they suggest that starting
patients on a dose of 250mgm
 2 was not beneficial.
The median duration of response and TTP were significantly
longer in Groups A and B compared with Group C (P¼0.030)
(Table 3). Despite a trend towards a shorter TTF and median
overall survival in Group C, there were no significant differences
across the arms for these parameters.
Safety and tolerability
All patients were evaluable for safety. At least one adverse event
was reported in all patients. However, grade 3–4 adverse events
possibly or probably related to the study treatment were reported
in less than half of the patients in each group (Table 4). Most of
these were related to haematological or gastrointestinal (GI) events
(Table 4). Grade 3–4 neutropenia with fever or infection was
infrequent. Although anaemia was common, it was infrequently
reported at grade 3–4 level of severity (Table 4). Diarrhoea was the
most common GI event, occurring in 85% of patients, although
grade 3–4 diarrhoea was less frequent (31, 21 and 27% in Groups
A, B and C, respectively) (Table 4). There were no significant
between-group differences for any of the adverse events reported.
In addition, analysis of adverse events at the different dose levels
showed no consistent evidence that toxicity increased with
increasing dosage. There was no difference between the three
treatment groups for the number of patients reporting X1 grade
3–4 adverse event considered to be possibly or probably
treatment-related (Group A, 42%; Group B, 48%; Group C, 49%).
Overall, 74 serious adverse events considered possibly or probably
related to study medication occurred in 39 patients.
Treatment discontinuations
At the designated study end date, 159 (96.95%). patients had
discontinued treatment (Group A, 97%; Group B, 95%; Group C,
99%) (Table 5). Disease progression resulted in proportionately
fewer discontinuations in Group B (57%) than in Groups A (72%)
and C (80%), and included fatalities arising from progressive
disease (one patient in each of Groups A and B, and two patients in
Group C). There was also one fatality: a case of aspiration
pneumonia secondary to vomiting in a patient in Group B
receiving the first cycle of irinotecan 250mgm
 2. Five (42%) of the
patients who discontinued treatment from Group B were receiving
the 250mgm
 2 dose option during cycle 1 at the time of
withdrawal. Adverse events leading to discontinuations are listed
in Table 5.
Pharmacokinetic parameters
The principal pharmacokinetic parameters for irinotecan and SN-
38 measured in 29 assessable patients are presented in Table 6. The
mean total body clearance values of irinotecan were similar across
all three groups and no relevant differences in dose-normalised
exposure were seen. Exposure to irinotecan and SN-38 increased
proportionally over the 250–500mgm
 2 irinotecan dose range. In
the population pharmacokinetic analysis, exposure to irinotecan
appeared to be increased in patients with PS 1 or 2, and in patients
with high alkaline phosphate levels.
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sDISCUSSION
The results of this phase II study confirm the activity of single-
agent irinotecan in patients with metastatic colorectal cancer who
have failed previous therapy with 5-FU. All three treatment
strategies investigated were active and demonstrated acceptable
tolerability patterns. Although almost all patients in the study had
X1 adverse event, less than half of the patients in each treatment
strategy had grade 3–4 toxicity.
The main aim of this study was to determine the optimal
irinotecan dosing regimen for the treatment of this population,
with the primary end point being response rate. The highest
overall response rate was seen in patients in Group B (13%). In this
group, four (21%) of the 19 patients receiving irinotecan
500mgm
 2 achieved a response. There was little difference in
the overall response rates in Groups A and C (8 and 9%,
respectively). An interesting observation in this study was the
relatively higher rate of progressive disease in Group C (44%)
compared with Groups A and B (36 and 31%). None of the
differences in response rate between the groups were statistically
significant. It is worth mentioning that the response rate observed
in Group A was unusually low, and less than that seen in published
studies of similar populations of patients treated with the same
schedule (Rougier et al, 1997; Van Cutsem et al, 1999). This may be
due to changes in first-line treatment that have occurred in recent
years; compared with patients treated in earlier studies, those in
the present study may have been more heavily pretreated with 5-
FU and oxaliplatin in the first-line setting, thus making them more
Table 1 Patient demographics and baseline characteristics
Treatment group
AB C
Number of patients (n); randomised (eligible and evaluable) 36 (31) 62 (51) 66 (62)
Gender; male:female (%) 50:50 71:29 62:38
Age in years; median (range) 60 (29–71) 59 (33–70) 60 (30–70)
Weight loss at baseline in relation to usual body weight (% of population)
p5% 88.9 85.5 87.9
45% 5.6 4.8 3.0
Unknown 5.6 9.7 9.1
Mean loss (kg) 1.1 0.9 1.0
WHO PS
Median 10 1
0( % ) 50.0 59.7 45.5
1( % ) 44.4 35.5 53.0
2( % ) 5.6 4.8 1.5
Primary tumour location
Colon 63.9 66.1 66.7
Rectum 36.1 33.9 33.3
Number of organs with metastatic involvement; median (range) 2 (1–3) 2 (1–3) 2 (1–4)
Synchronous metastases (%) 41.7 59.7 56.1
Sites of metastatic disease (%)
Liver 69.4 79.0 80.3
Liver alone 48.0 53.1 37.7
Liver and other organs 52.0 46.9 62.3
Lung 41.7 30.6 31.8
Peritoneum 11.1 4.8 13.6
Lymph nodes 11.1 21.0 22.7
Colon 0 6.5 1.5
All others
a 27.8 22.6 30.3
Median (range) time to randomisation (months) from
First diagnosis 18.1 (4.7–82.3) (n¼35) 12.7 (3.0–76.3) (n¼61) 12.6 (3.2–160.1) (n¼66)
First metastasis 9.1 (0.0–54.7) (n¼35) 9.0 (0.6–42.7) (n¼62) 8.1 (0.1–51.6) (n¼65)
Prior anticancer treatment (% of patients)
Surgery 97.2 98.4 97.0
Radiotherapy 30.6 21.0 22.7
Adjuvant chemotherapy 33.3 25.8 21.2
At least one symptom at baseline
(% of patients) 72.2 62.9 77.3
At least one abnormal laboratory value at baseline (% of patients) 97.2 95.2 93.9
aSoft tissue, bone, adrenal, pelvis, abdomen, pleura, retroperitoneum, spleen, mediastinum, skin. WHO, World Health Organization.
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schemotherapy resistant. Despite the lower response rate in Group
A, it is within the CIs of previous studies and so can be considered
representative.
The lack of a significant difference in overall response rates
between the groups may reflect the fact that the median dose
intensity of irinotecan delivered was relatively constant across the
three groups, despite a proportion of patients in Groups B (34%)
and C (9%) receiving an irinotecan dose of 500mgm
 2. This
finding is probably due mainly to the fact that a disproportionate
number of patients (more than one-third) in each of Groups B and
C never received a dose of more than 250mgm
 2, and so were
possibly underdosed. The likelihood of underdosing in Groups B
and C is supported by the observation that only 6% of patients in
Group A required dose reduction from 350 to 250mgm
 2.
There were no significant differences between Groups A and B in
TTP or overall survival. This may be due to an insufficient
powering of the study and/or too small a difference in response
rates. A previous meta-analysis conducted in patients with
advanced colorectal cancer reported that only large differences
in response rate correspond to a significant difference in TTP
(Buyse et al, 2000). Both TTP and duration of response were
significantly shorter in Group C than in Groups A and B, and there
was also a trend for a shorter overall survival in this group. The
relatively poor efficacy seen in Group C may have been due to a
combination of underdosing (i.e. a significant number of patients
receiving irinotecan 250mgm
 2) and the small number of patients
who received the high dose of irinotecan (500mgm
 2) (six
patients or 9%).
There was a trend towards a better safety profile in Group B.
Grade 3–4 neutropenia was 31% in Group B, 47% in A and 44% in
Group B. Similarly, there was less grade 3–4 diarrhoea in Group B
as compared with Groups A and C (21 vs 31 and 27%,
respectively), despite 34% of patients receiving the highest
irinotecan dose. We cannot exclude the contribution to this
difference of imbalances in gender ratio (more male patients in
Group B) and PS (more patients with PS¼0 in Group B). However,
it is possible that the results reflect the aim of the strategy adopted
in Group B, which was to avoid subjecting patients to higher doses
than they were able to tolerate. Indeed 10 out of 12 patients in
Group B who withdrew from the study due to treatment-related
adverse events received the lowest dose of irinotecan (250mgm
 2)
and therefore would not have tolerated an increased dose of
irinotecan. However, it should also be noted that severe toxicity
leading to treatment discontinuation occurred more frequently in
Group B despite the low dose given to all patients in the first cycle.
In Group C, despite the strategy of basing the initial irinotecan
Table 2 Extent of exposure to irinotecan
Treatment group
ABC
Number of patients exposed 36 62 66
Number of treatment cycles 216 370 333
Median (range) number of cycles 6 (1–24) 5 (1–21) 4 (1–15)
Median (range) treatment duration (weeks) 18 (3–78) 16 (3–64) 13 (3–46)
Cycles by dose (% of cycles)
a
250mgm
 2 34 1 3 3
350mgm
 2 92 30 51
500mgm
 2 —2 7 8
Median actual dose intensity (mgm
 2week
 1) (95% CI) 114.21 (76.14–119.21) 101.36 68.22–158.17) 106.69 (67.11–170.93)
Median cumulative dose (mgm
 2) (95% CI) 1948.80 (314.65–8373.08) 1564.26 (247.52–10100.00) 1326.77 (249.73–4899.13)
At least one dose increase (% of patients) — 63 —
At least one dose reduction
b
% of patients 17 15 17
% of cycles 4 3 5
At least one cycle delayed
b
% of patients 36 40 36
% of cycles 19 15 15
aSome cycles were administered at intermediate doses.
bFor any reason (see text).
Table 3 Efficacy results
Parameter Group A (n¼36) Group B (n¼62) Group C (n¼66) P-value
a
Overall response rate, % (95% CI)
b 8 (1.8–22.5) 13 (5.7–23.9) 9 (3.4–18.7)
Overall response rate, % (95% CI)
b Per protocol 10 (2.0–25.8) 16 (7.0–28.6) 10 (3.6–19.9)
250mgm
 2c — (0/16) 0% (2/20) 10% NC
350mgm
 2c (3/31) 10% (4/16) 25% (4/36) 11% NC
500mgm
 2c — (4/19) 21% (0/6) 0% NC
Tumour growth control rate (%) 58% 60% 50% NC
Progressive disease (%) 36% 31% 44% NC
Median duration of response (months) 6.4 6.6 4.3 0.03
Median TTP (months) 4.1 4.2 3.0 0.019
Median TTF (months) 3.7 3.4 2.5 NS
Median overall survival (months) 12.5 12.1 10.9 NS
Results are presented for the ITT population, unless otherwise stated.
aA vs C and B vs C.
bThere were no CRs.
cResponse rate is expressed as a percentage of patients treated at
that dose level as their highest dose in each group. CI, confidence interval; NC, not calculated; NS, not significant.
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sdose on predetermined risk factors, patients administered the
250mgm
 2 dose demonstrated higher rates of grade 3–4 anaemia
and diarrhoea compared with those receiving the 350 and
500mgm
 2 doses.
This study demonstrates that intrapatient dose escalation
based on toxicity in the preceding cycle dose, as practised in
Group B, is feasible. Although the increase in the response
rate over the whole group was modest compared with the
standard irinotecan dose, clinical benefit may be seen in those
patients who are able to receive 350 and 500mgm
 2, which, in this
study, was associated with a response rate of 25 and
21%, respectively. The findings of our study in pretreated patients
are in agreement with those of a nonrandomised study in
previously untreated patients (Ychou et al, 2002): the greater
proportion of patients who are able to receive the higher dose and
the higher response rate achieved in the latter study compared
with our study is probably a reflection of interstudy differences in
the starting dose, dose escalation guidelines and in the study
population (previous treatment compared with no previous
treatment).
Table 4 Adverse events
Treatment group: n (% of patients)
Grade 3–4 adverse events
a A( n¼36) B (n¼62) C (n¼66)
At least one grade 3–4 adverse event
a 15 (42) 30 (48) 32 (48)
Haematological
Leukopenia 9 (25) 15 (24) 21 (32)
Neutropenia 17 (47) 19 (31) 29 (44)
Anaemia 3 (8) 1 (2) 5 (8)
Infection (grade 3–4 neutropenia present) 2 (6) 0 2 (3)
Fever without infection (grade 3–4 neutropenia present) 0 2 (3) 3 (5)
Gastrointestinal (GI)
Vomiting 5 (14) 10 (16) 6 (9)
Diarrhoea 11 (31) 13 (21) 18 (27)
Nausea 4 (11) 7 (11) 7 (11)
All other GI events
b 5 (14) 5 (8) 4 (6)
Other adverse events
Fatigue 3 (8) 7 (11) 8 (12)
Fever (grade 3–4 neutropenia absent) 0 1 (2) 3 (5)
Infection (grade 3–4 neutropenia absent) 2 (6) 1 (2) 3 (5)
aPossibly or probably related to study treatment.
bAnorexia, five (3%) cases; cholinergic syndrome, three (2%) cases; GI pain, two (1%) cases; dehydration, three (2%) cases;
stomatitis, one (1%) case.
Table 5 Patient discontinuations
Treatment group: n (% of patients)
A( n¼36) B (n¼62) C (n¼66)
No. of patients still on treatment at cutoff date 1 (3) 3 (5) 1 (2)
Total treatment discontinuations 35 (97) 59 (95) 65 (99)
Nonfatal reasons
Progressive disease 25 (69) 34 (55) 51 (77)
Treatment-related adverse event 2 (6) 12 (19) 6 (9)
Adverse events leading to discontinuation
a
Fatigue 1 (3) 3 (5) 2 (3)
Vomiting 1 (3) 3 (5) 2 (3)
Diarrhoea — 4 (7) 2 (3)
Nausea — 2 (3) 2 (3)
Neutropenia — 2 (3) 1 (2)
Febrile neutropenia — 2 (3) —
Neutropenic infection 1 (3) — —
Infection — — 2 (3)
Fever (infection absent) — 1 (2) —
All other nonfatal events
b — 5 (8) 1 (2)
Patient refusal 1 (3) 4 (7) 1 (2)
Other 6 (17) 7 (11) 4 (6)
Fatal reasons
Death due to treatment-related adverse events — 1 (2) —
Death due to progressive disease 1 (3) 1 (2) 2 (3)
Cardio-respiratory failure — — 1 (2)
aNot mutually exclusive. Patients may have discontinued treatment for more than one adverse event reason.
bGroup B: aggravation reaction, two (3%) cases; anorexia, one (2%)
case; dehydration, one (2%) case; small bowel obstruction, one (2%) case. Group C: anorexia, one (2%) case.
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of dose optimisation according to the baseline risk characteristics
identified in our study protocol (as practised in Group C) appeared
not to be an appropriate approach. This may be because the risk
characteristics identified were not valid in this setting or that the
algorithm for dose assignment was not relevant. Further investiga-
tion is required to clarify this.
In conclusion, the data from our randomised phase II study
suggest that individual dose optimisation based on toxicity in the
preceding cycle is feasible and merits further investigation.
Increasing the dose of irinotecan to 500mgm
 2 can be of benefit
in selected patients. It will be necessary to identify the most
appropriate starting dose, as the dose of 250mgm
 2 used in this
study was possibly too conservative. Data from pharmacogenomic
research are likely to be useful in the future for identifying the
most appropriate starting dose of irinotecan for individual
patients.
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